A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CheckMate 915
- Sponsors Bristol-Myers Squibb
- 08 Sep 2017 Planned number of patients changed from 1483 to 900.
- 08 Sep 2017 Planned End Date changed from 10 Jan 2023 to 17 Feb 2023.
- 08 Sep 2017 Planned primary completion date changed from 29 Nov 2020 to 8 Nov 2020.